Acta clinica Croatica, Vol. 45 No. 1, 2006.
Stručni rad
Benefit from Beta Interferon in the Treatment of Multiple Sclerosis
Marija Bošnjak-Pašić
Marijana Lisak
Melita Uremović
Branka Vidrih
Vida Demarin
Sažetak
Over the past twelve years, beta interferons 1a and 1b have been increasingly used as immunomodulatory agents in the treatment of multiple sclerosis as well as for prophylaxis of disease progression. In Croatia, the cost of beta interferons 1a and 1b has been covered by the Croatian Institute of Health Insurance since 1997. Despite numerous doubts about their real benefit, having in mind their price, side effects and occurrence of neutralizing antibodies, numerous clinical trials have confirmed their efficacy. The most efficient are interferon beta 1a (Rebif® in a dose of 12 MIU, subcutaneously, three times per week), interferon beta 1b (Betaferon® in a dose of 8 MIU, subcutaneously, every other day) and interferon beta-1a (Avonex® in a dose of 6 MIU weekly intramuscularly).
Ključne riječi
Interferons - therapeutic use; Multiple sclerosis - drug therapy; Interferons - adverse effects; Treatment outcome; Clinical trials
Hrčak ID:
14048
URI
Datum izdavanja:
1.3.2006.
Posjeta: 2.514 *